Biotechnology

Willkie has extensive experience in the health care and life sciences field, both in the United States and abroad. We represent companies and investors in the areas of biotechnology, pharmaceuticals, medical technology, wellness and providers. Our work includes corporate transactions, mergers and acquisitions, joint venture transactions, compliance matters, IP issues, patent litigation and counseling, and general litigation.

Willkie has extensive experience in the health care and life sciences field, both in the United States and abroad. We represent companies and investors in the areas of biotechnology, pharmaceuticals, medical technology, wellness and providers. Our work includes corporate transactions, mergers and acquisitions, joint venture transactions, compliance matters, IP issues and general litigation.

Capital Markets

  • Athersys, Inc.: Represented ING Barings (Furman Selz) in a private placement of $10 million of Class C convertible preferred stock of Athersys, a clinical stage biopharmaceutical and genomics company.

    Clovis Oncology: Represented this developer and marketer of anti-cancer drugs since its inception and in various acquisition-related transactions (see M&A section above), principal licensing agreements and the following financings:

    • $316.2 million public offering of common stock.
    • $287.5 million 144A offering of convertible senior notes.
    • $275 million underwritten public offering of shares of its common stock.
    • $75 million underwritten public offering of shares of its common stock.

    Epigenomics AG: Represented Morgan Stanley Bank AG on the rights issue of German molecular diagnostics company Epigenomics, a developer and commercializer of proprietary products for the screening and diagnosis of cancer.

    Synageva BioPharma Corp.: Represented the underwriters, led by joint book-running managers Goldman, Sachs & Co. and J.P. Morgan Securities LLC, in Synageva’s $308 million public offering of common stock.

    Synageva BioPharma Corp.: Represented Morgan Stanley and J.P. Morgan as joint book-running managers for the $90 million underwritten public offering of the common stock of Synageva, a clinical stage biopharmaceutical company.

- Collapse

Litigation and Investigation

  • SeraCare Life Sciences, Inc.: Conducted an internal investigation on behalf of the Audit Committee of SeraCare.

- Collapse

Mergers & Acquisitions, PE & VC Investments, Joint Ventures and Other Business Combinations

  • Ekkio/Q-Biologicals: Represented Ekkio and its portfolio company, Amatsigroup, in the acquisition of Q-Biologicals, a leading provider of process development and biomanufacturing services.

    Tikehau/Cisbio Bioassays/Abenex: Represented Tikehau on the financing aspects of the acquisition of Cisbio Bioassays by Abenex.

    Valtech Cardio/HeartWare: Represented Valtech Cardio in its proposed acquisition by HeartWare, a combination that will help deliver transformative products to patients with advanced heart failure and degenerative heart conditions.

    Warburg Pincus/Allos Therapeutics, Inc.: Represented Warburg as the largest selling shareholder in the $206 million sale of this biopharmaceutical developer to Spectrum Pharmaceuticals.

- Collapse